

# Miles Fisher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10458892/publications.pdf>

Version: 2024-02-01

45  
papers

13,067  
citations

687363

13  
h-index

315739

38  
g-index

50  
all docs

50  
docs citations

50  
times ranked

16960  
citing authors

#	ARTICLE	IF	CITATIONS
1	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	2.2	5,247
2	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
3	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
4	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	683
5	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). <i>Atherosclerosis</i> , 2012, 223, 1-68.	0.8	414
6	SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. <i>Nature Reviews Cardiology</i> , 2020, 17, 761-772.	13.7	372
7	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 877-886.	11.4	245
8	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 5-115.	1.8	220
9	Diabetes, left ventricular systolic dysfunction, and chronic heart failure. <i>European Heart Journal</i> , 2008, 29, 1224-1240.	2.2	184
10	Increasing Physical Activity in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2003, 26, 1186-1192.	8.6	167
11	Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 697-703.	11.4	70
12	Evaluation of Factors Related to Glycemic Management in Professional Cyclists With Type 1 Diabetes Over a 7-Day Stage Race. <i>Diabetes Care</i> , 2020, 43, 1142-1145.	8.6	14
13	Thiazolidinediones in Patients with Diabetes Mellitus and Heart Failure. <i>American Journal of Cardiovascular Drugs</i> , 2006, 6, 297-304.	2.2	12
14	Diabetes ? a state of premature cardiovascular death. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 183-184.	0.2	10
15	The HOPE Study: practical implications for people with diabetes. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2000, 17, 191-194.	0.2	9
16	Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2) Tj ETQq0.40 rgBT / Overlock 1		
17	A pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 402-407.	4.4	6
18	Review: Comparing cardiovascular outcomes in diabetes studies. <i>British Journal of Diabetes and Vascular Disease</i> , 2006, 6, 111-118.	0.6	4

#	ARTICLE	IF	CITATIONS
19	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 553-554.	0.2	4
20	Cardiovascular safety and DPP4 inhibitors. Practical Diabetes, 2013, 30, 78-81.	0.3	4
21	Recent cardiovascular safety trials with antidiabetic drugs: time to change the guidelines!. Practical Diabetes, 2015, 32, 319-320.	0.3	4
22	Statins for people with type 1 diabetes: when should treatment start?. Practical Diabetes, 2016, 33, 10-11.	0.3	4
23	Inconclusive effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. Practical Diabetes, 2017, 34, 302-303.	0.3	4
24	Management of atrial fibrillation in diabetes. Practical Diabetes, 2018, 35, 27-31.	0.3	4
25	Pharmacologic management of patients with both heart failure and diabetes. Current Heart Failure Reports, 2009, 6, 126-132.	3.3	3
26	Lessons from the professionals: diabetes and pro cycling. Practical Diabetes, 2013, 30, 266-270.	0.3	3
27	SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist. Practical Diabetes, 2016, 33, 266-268a.	0.3	3
28	PROactive: early criticism not justified?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2005, 22, 323-324.	0.2	2
29	How safe are DPP4 inhibitors?. Practical Diabetes, 2013, 30, 352.	0.3	2
30	Dapagliflozin and DAPA-HF: from glycaemic control to heart failure therapy. Practical Diabetes, 2019, 36, 192-193.	0.3	2
31	What are the beneficial and adverse effects of aspirin in diabetic patients?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2004, 21, 131-133.	0.2	1
32	Drug development and licensing in diabetes. Practical Diabetes, 2016, 33, 60-64.	0.3	1
33	Is diabetes still a state of premature cardiovascular death?. Practical Diabetes, 2016, 33, 285-290.	0.3	1
34	Diabetes and stroke. Practical Diabetes, 2019, 36, 126-131.	0.3	1
35	Results of the ASCEND study: time to abandon aspirin for the primary prevention of cardiovascular disease in people with diabetes. Practical Diabetes, 2019, 36, 4.	0.3	1
36	The role of exercise in diabetes management. Nursing and Residential Care, 2003, 5, 526-528.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Residual cardiovascular risk and practical management of type 2 diabetes. British Journal of Diabetes and Vascular Disease, 2006, 6, S17-S23.	0.6	0
38	Thiazolidinediones: the answer to everyone's dreams?. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2006, 23, 381-383.	0.2	0
39	Type 2 diabetes: getting off to a good start. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 6-8.	0.2	0
40	The Muscle Metaboreflex in Patients with Diabetic Autonomic Neuropathy. British Journal of Diabetes and Vascular Disease, 2010, 10, 238-245.	0.6	0
41	From bicycle to Krebs' cycle. Practical Diabetes, 2013, 30, 262-263.	0.3	0
42	Cardiovascular safety and GLP-1 receptor agonists. Practical Diabetes, 2013, 30, 242-245.	0.3	0
43	Saroglitazar. Practical Diabetes, 2016, 33, 142-143a.	0.3	0
44	More cardiovascular outcomes trials in people with diabetes: time to change the NICE guidelines. Practical Diabetes, 2018, 35, 193-194.	0.3	0
45	A century of insulin: from lifesaving discovery to a journey of scientific evolution!. Practical Diabetes, 2021, 38, 7-12.	0.3	0